
|Videos|August 30, 2022
Comparing Approved Options for Androgen Inhibition in the mCSPC Setting
Author(s)Marc Matrana, MD
Discussion centered around androgen receptor inhibition/androgen synthesis inhibition and comparison of available, approved options for each.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5

















